



Tecvayli in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

ONCOLOGY · BCMAxCD3 BISPECIFIC MYELOMA

The clinical situation

Tecvayli (teclistamab) is a humanised BCMAxCD3 bispecific T-cell engager for heavily pre-treated relapsed/refractory multiple myeloma (typically after four prior lines including a PI, IMiD, and anti-CD38). Manufactured by Janssen. Administration is subcutaneous on a step-up schedule (0.06, 0.3, then 1.5 mg/kg) followed by 1.5 mg/kg weekly; the step-up phase requires inpatient CRS/ICANS monitoring at a facility capable of tocilizumab administration.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating haematologist documents prior-line sequence, performance status, and cytopenia/infection baseline.
- 2 Administering centre confirmed.** A Saudi tertiary haematology unit with CRS/ICANS monitoring capability is nominated; step-up beds booked.
- 3 SFDA named-patient application.** Clinical rationale, patient reference, centre-capability attestation, and dosing plan are filed.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner under validated cold chain.
- 5 Step-up admission & ongoing therapy.** The tertiary centre admits for step-up, manages CRS/ICANS, transitions to weekly outpatient maintenance.

Indicative economics

Reference US cash-pay range: USD 40,000–48,000 per month at 1.5 mg/kg weekly maintenance (weight-based; drug-only reference; Reserve Meds provides a transparent delivered quote at intake). Inpatient step-up admission is separate local cost.

Indicative first-dose timing

7–14 days from a complete SFDA application to first-dose step-up admission, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and SFDA review, keyed to the BCMA-bispecific rationale. **Logistics.** Validated cold-chain shipment to the nominated tertiary centre. **Concierge case lead.** Named point of contact through step-up and maintenance cadence. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating haematologist and administering centre.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Tecvayli × Saudi Arabia first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/tecvayli-saudi-arabia.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team